164 related articles for article (PubMed ID: 26390246)
1. The WHO's medical eligibility criteria for contraceptive use: 20 years of global guidance.
Altshuler AL; Gaffield ME; Kiarie JN
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):451-9. PubMed ID: 26390246
[TBL] [Abstract][Full Text] [Related]
2. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection.
Tepper NK; Curtis KM; Cox S; Whiteman MK
MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(14):405-410. PubMed ID: 32271729
[TBL] [Abstract][Full Text] [Related]
3. Canadian Contraception Consensus (Part 2 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
[TBL] [Abstract][Full Text] [Related]
4. Canadian Contraception Consensus (Part 1 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
[TBL] [Abstract][Full Text] [Related]
5. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection.
Tepper NK; Krashin JW; Curtis KM; Cox S; Whiteman MK
MMWR Morb Mortal Wkly Rep; 2017 Sep; 66(37):990-994. PubMed ID: 28934178
[TBL] [Abstract][Full Text] [Related]
6. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(24):449-52. PubMed ID: 22717514
[TBL] [Abstract][Full Text] [Related]
7. Use of the World Health Organization's Medical Eligibility Criteria for Contraceptive Use Guidance in sub-Saharan African Countries: A Cross-Sectional Study.
Chen MJ; Gaffield ME; Kiarie J
Glob Health Sci Pract; 2016 Sep; 4(3):506-10. PubMed ID: 27688720
[TBL] [Abstract][Full Text] [Related]
8. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
Curtis KM; Tepper NK; Jatlaoui TC; Berry-Bibee E; Horton LG; Zapata LB; Simmons KB; Pagano HP; Jamieson DJ; Whiteman MK
MMWR Recomm Rep; 2016 Jul; 65(3):1-103. PubMed ID: 27467196
[TBL] [Abstract][Full Text] [Related]
9. Reproductive Planning: Short-Acting Reversible Contraceptives.
Wilson ML; Godfrey EM; Glass S; Zhang Y
FP Essent; 2024 Mar; 538():13-24. PubMed ID: 38498325
[TBL] [Abstract][Full Text] [Related]
10. New IPPF statement on breastfeeding, fertility and post-partum contraception.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1990 Apr; 24(2):2-4. PubMed ID: 12316285
[TBL] [Abstract][Full Text] [Related]
11. Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response.
Nene Z; Hofmeyr GJ; Patel M; Panday M; Rees H; Makua M; Pillay Y
S Afr Med J; 2018 Jul; 108(8):629-631. PubMed ID: 30182875
[TBL] [Abstract][Full Text] [Related]
12. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: A systematic review.
Carr SL; Gaffield ME; Dragoman MV; Phillips S
Contraception; 2016 Sep; 94(3):253-61. PubMed ID: 25869631
[TBL] [Abstract][Full Text] [Related]
13. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
[TBL] [Abstract][Full Text] [Related]
14. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
15. Neglect of attention to reproductive health in women with HIV infection: contraceptive use and unintended pregnancies in the Swiss HIV Cohort Study.
Aebi-Popp K; Mercanti V; Voide C; Nemeth J; Cusini A; Jakopp B; Nicca D; Rasi M; Bruno A; Calmy A; Martinez de Tejada B;
HIV Med; 2018 May; 19(5):339-346. PubMed ID: 29336516
[TBL] [Abstract][Full Text] [Related]
16. Behavioral interventions for improving contraceptive use among women living with HIV.
Lopez LM; Hilgenberg D; Chen M; Denison J; Stuart G
Cochrane Database Syst Rev; 2013 Jan; (1):CD010243. PubMed ID: 23440846
[TBL] [Abstract][Full Text] [Related]
17. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(26):878-83. PubMed ID: 21734635
[TBL] [Abstract][Full Text] [Related]
18. Lactation and contraception.
Bhardwaj NR; Espey E
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):496-503. PubMed ID: 26390248
[TBL] [Abstract][Full Text] [Related]
19. Postpartum options: matching the method to individual needs.
Townsend S
Netw Res Triangle Park N C; 1990 Aug; 11(3):12-5. PubMed ID: 12342904
[TBL] [Abstract][Full Text] [Related]
20. Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry.
Godfrey EM; Mody S; Schwartz MR; Heltshe SL; Taylor-Cousar JL; Jain R; Sufian S; Josephy T; Aitken ML
Contraception; 2020 Jun; 101(6):420-426. PubMed ID: 32109430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
